SI3660073T1 - Poli (laktid-co-glikolid) z nizkim izpadom - Google Patents

Poli (laktid-co-glikolid) z nizkim izpadom

Info

Publication number
SI3660073T1
SI3660073T1 SI200832213T SI200832213T SI3660073T1 SI 3660073 T1 SI3660073 T1 SI 3660073T1 SI 200832213 T SI200832213 T SI 200832213T SI 200832213 T SI200832213 T SI 200832213T SI 3660073 T1 SI3660073 T1 SI 3660073T1
Authority
SI
Slovenia
Prior art keywords
glycolide
lactide
burst
poly
low
Prior art date
Application number
SI200832213T
Other languages
English (en)
Inventor
Eric Dadey
John Middleton
Richard L. Norton
Original Assignee
Tolmar International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Limited filed Critical Tolmar International Limited
Publication of SI3660073T1 publication Critical patent/SI3660073T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/88—Post-polymerisation treatment
    • C08G63/90—Purification; Drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
SI200832213T 2007-02-15 2008-02-13 Poli (laktid-co-glikolid) z nizkim izpadom SI3660073T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90143507P 2007-02-15 2007-02-15
EP19203071.6A EP3660073B1 (en) 2007-02-15 2008-02-13 Low-burst poly(lactide-co-glycolide)

Publications (1)

Publication Number Publication Date
SI3660073T1 true SI3660073T1 (sl) 2023-10-30

Family

ID=39504385

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200831512T SI2115029T1 (sl) 2007-02-15 2008-02-13 Poli-(laktid/glikolid) z zmanjšanim takojšnjim učinkom sproščanja in metode za izdelavo polimerov
SI200832098T SI3202814T1 (sl) 2007-02-15 2008-02-13 Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov
SI200832213T SI3660073T1 (sl) 2007-02-15 2008-02-13 Poli (laktid-co-glikolid) z nizkim izpadom

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200831512T SI2115029T1 (sl) 2007-02-15 2008-02-13 Poli-(laktid/glikolid) z zmanjšanim takojšnjim učinkom sproščanja in metode za izdelavo polimerov
SI200832098T SI3202814T1 (sl) 2007-02-15 2008-02-13 Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov

Country Status (16)

Country Link
US (7) US9187593B2 (sl)
EP (3) EP2115029B1 (sl)
JP (3) JP5342459B2 (sl)
CA (1) CA2678350C (sl)
CY (2) CY1116785T1 (sl)
DK (3) DK3202814T3 (sl)
ES (3) ES2956244T3 (sl)
FI (1) FI3660073T3 (sl)
HK (1) HK1138303A1 (sl)
HR (3) HRP20231117T3 (sl)
HU (3) HUE063170T2 (sl)
LT (2) LT3202814T (sl)
PL (3) PL3660073T3 (sl)
PT (3) PT3202814T (sl)
SI (3) SI2115029T1 (sl)
WO (1) WO2008100532A1 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
DK3202814T3 (da) 2007-02-15 2019-11-25 Tolmar Therapeutics Inc Poly-(laktid/glykolid) med lav udskilning og fremgangsmåder til at fremstille polymerer
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
CN102112107A (zh) * 2008-06-03 2011-06-29 托马医疗科技公司 具有改进的释放动力学特征的控制释放共聚物制剂
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PT2394664T (pt) 2010-05-31 2016-09-06 Farm Rovi Lab Sa Composição depot para injetável antipsicótico
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
CN103421172B (zh) * 2012-05-23 2016-01-20 上海现代药物制剂工程研究中心有限公司 一种生物可降解聚酯的纯化工艺
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
AU2014249008B2 (en) 2013-03-11 2018-12-06 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
JP5959728B2 (ja) * 2013-04-11 2016-08-02 三井化学株式会社 乳酸―グリコール酸共重合体の製造法またはその塩の製造法
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
ES2808150T3 (es) 2014-11-07 2021-02-25 Indivior Uk Ltd Regímenes de dosificación de buprenorfina
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN108498456B (zh) * 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
ES2952213T3 (es) 2020-02-06 2023-10-30 Ocular Therapeutix Inc Composiciones y métodos para tratar enfermedades oculares
US20240000797A1 (en) 2020-09-30 2024-01-04 Tolmar International Limited Biodegradable polymer delivery system for extended delivery of testosterone

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DE3641692A1 (de) 1986-12-06 1988-06-09 Boehringer Ingelheim Kg Katalysatorfreie resorbierbare homopolymere und copolymere
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP0452111B1 (en) 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
PT754032E (pt) 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
PT814778E (pt) 1995-03-10 2001-11-30 Roche Diagnostics Gmbh Formas de administracao farmaceuticas contendo polipeptidos sob a forma de microparticulas e processo para a sua preparacao
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP4317599B2 (ja) * 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
IL135415A0 (en) 1997-10-03 2001-05-20 Macromed Inc Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE60118575T3 (de) 2000-08-07 2011-05-19 Takeda Pharmaceutical Co. Ltd. Milchsäurepolymer und verfahren zu dessen herstellung
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
JP5188670B2 (ja) * 2001-06-29 2013-04-24 武田薬品工業株式会社 徐放性組成物およびその製造法
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
KR20070083941A (ko) * 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
DK2079767T3 (da) * 2006-10-11 2014-10-27 Tolmar Therapeutics Inc Fremstilling af bionedbrydelige polyestere med lave burst-egenskaber ved ekstraktion med et superkritisk fluid
DK3202814T3 (da) 2007-02-15 2019-11-25 Tolmar Therapeutics Inc Poly-(laktid/glykolid) med lav udskilning og fremgangsmåder til at fremstille polymerer

Also Published As

Publication number Publication date
EP3202814A1 (en) 2017-08-09
JP5342459B2 (ja) 2013-11-13
HRP20231117T3 (hr) 2023-12-22
DK3202814T3 (da) 2019-11-25
US20170216395A1 (en) 2017-08-03
EP3660073A1 (en) 2020-06-03
JP2015127351A (ja) 2015-07-09
HUE047775T2 (hu) 2020-05-28
PT2115029E (pt) 2015-10-26
US20160106847A1 (en) 2016-04-21
PL2115029T3 (pl) 2016-01-29
US9187593B2 (en) 2015-11-17
LT3660073T (lt) 2023-10-10
ES2755374T3 (es) 2020-04-22
DK2115029T3 (en) 2015-10-05
CY1122304T1 (el) 2021-01-27
SI3202814T1 (sl) 2019-12-31
HRP20192055T1 (hr) 2020-02-21
EP3202814B1 (en) 2019-10-16
PL3660073T3 (pl) 2023-12-27
US20220202941A1 (en) 2022-06-30
US10206970B2 (en) 2019-02-19
US20100292195A1 (en) 2010-11-18
SI2115029T1 (sl) 2016-01-29
ES2956244T3 (es) 2023-12-15
ES2550014T3 (es) 2015-11-03
HUE025842T2 (en) 2016-04-28
EP2115029B1 (en) 2015-09-16
WO2008100532A1 (en) 2008-08-21
HRP20150997T1 (hr) 2015-12-18
US9655970B2 (en) 2017-05-23
JP5848290B2 (ja) 2016-01-27
EP3660073B1 (en) 2023-07-12
US20190209643A1 (en) 2019-07-11
CA2678350C (en) 2015-11-17
JP2013224339A (ja) 2013-10-31
DK3660073T3 (da) 2023-09-18
US9561282B2 (en) 2017-02-07
US11147880B2 (en) 2021-10-19
CA2678350A1 (en) 2008-08-21
US11717572B2 (en) 2023-08-08
US9974824B2 (en) 2018-05-22
US20180311305A1 (en) 2018-11-01
US20170095560A1 (en) 2017-04-06
HUE063170T2 (hu) 2024-01-28
JP6195587B2 (ja) 2017-09-13
HK1138303A1 (en) 2010-08-20
LT3202814T (lt) 2019-12-10
PT3202814T (pt) 2019-11-26
EP2115029A1 (en) 2009-11-11
CY1116785T1 (el) 2017-03-15
PL3202814T3 (pl) 2020-01-31
JP2010519218A (ja) 2010-06-03
FI3660073T3 (fi) 2023-09-11
PT3660073T (pt) 2023-08-31

Similar Documents

Publication Publication Date Title
LT3660073T (lt) Poli(laktidas-ko-glikolidas) su lėtu pradiniu atsipalaidavimu
ZA200808637B (en) Polymers
IL185609A0 (en) Multi function senssor
AP2010005314A0 (en) Nanodispersian
GB0820231D0 (en) Airbagmodul, airbagmodulanordung und befestigungsverfahren
GB0719064D0 (en) simple steps
IL200613A0 (en) Erythromycin-based macrolides
TWI347625B (en) Wireless switch module
HK1126892A1 (en) Wireless switch module
GB0720530D0 (en) Readers
EP2026825A4 (en) FURANON-INITIATED POLYMERS
EP2134587A4 (en) INTERMEDIATE TRACTION BAR ARRANGEMENT
GB0617450D0 (en) Liverstock carriers
GB0718456D0 (en) Molecular knex-structures
GB0724985D0 (en) Molecular KNEX-structures
GB0701035D0 (en) .
GB0701036D0 (en) .
GB0722633D0 (en) Flipper
IL181852A0 (en) D.s-hom
GB0702065D0 (en) Just one more two
GB0709794D0 (en) Step
IL182708A0 (en) Silivirax porta
GB0707456D0 (en) Tolerance
GB0713332D0 (en) Richochet (Triorich)
GB0713326D0 (en) Richochet (Hexachart)